Bayer Pharma’s Overhaul Not Slowing Down Deal Making, Says BD Chief

Bayer Pharma's Overhaul:
Bayer Pharma's business development chief has stated that the company's ongoing overhaul is not slowing down its deal-making activities.

Focus on Core Mission:
The company is focusing on sourcing new, innovative compounds and replenishing its pipeline, indicating a commitment to its core mission.

Biotech IPO Window:
Analysts at PwC predict that the biotech IPO window will gradually reopen in 2024, with a focus on companies with strong clinical data.

M&A Activity:
M&A levels in the biotech sector are expected to remain healthy in 2024, with dealmakers focusing on margin accretion and strategic gaps.

Precision Medicines:
Precision medicines, particularly in areas like oncology and immunology, will continue to be a focus for dealmaking in 2024.

Bayer's Restructuring:
Bayer is undergoing significant restructuring, including layoffs and the elimination of middle management positions, in an effort to save $2.15 billion.